Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Natera, Inc. (NTRA): Form 4 insider transaction
The company’s President and Chief Business Officer reported open-market sales tied to RSU tax withholding under a Rule 10b5-1(c) plan. On 10/27/2025, 781 shares of common stock were sold at $192.324. On 10/28/2025, 928 shares were sold at $191.4619. Following these transactions, the reporting person directly owned 150,699 shares.
Natera (NTRA) reported insider activity by its Chief Financial Officer. On 10/22/2025, the CFO sold 920 shares at $186.68 and converted 1,250 Restricted Stock Units (RSUs) into common stock. Additional sales included 495 shares at $187.16 on 10/23/2025 (to satisfy tax withholding on RSU vesting) and 755 shares at $196.77 on 10/24/2025. Following these transactions, the officer directly owned 69,189 shares. The sales on 10/22 and 10/24 were made under a Rule 10b5-1 plan adopted on June 14, 2024.
Natera, Inc. (NTRA) insider transaction: A reporting person who serves as Executive Chairman and Director sold 10,000 shares of Natera common stock on 10/20/2025 at a price of $190 per share, coded as an open-market sale (S). The trade was executed under a Rule 10b5-1 trading plan adopted on June 13, 2025.
Following the transaction, the reporting person beneficially owned 2,320,852 shares directly and 5,000 shares indirectly through a spouse.
Natera, Inc. (NTRA) — Form 4 insider activity: Co‑founder and director reported RSU vesting and a related tax sale. On 10/20/2025, 190 Restricted Stock Units were converted to common stock (code M). On 10/21/2025, 93 shares were sold at $187.95 (code S) to satisfy tax withholding, pursuant to a Rule 10b5‑1(c) instruction. Following these transactions, the reporting person beneficially owned 236,302 shares directly. In addition, 28,032 shares are held indirectly by Caraluna 1 Trust and 28,032 shares by Caraluna 2 Trust.
Natera (NTRA) reported an insider equity change by its SEC. and Chief Legal Officer. On 10/20/2025, 856 shares of common stock were acquired through the vesting of RSUs, and on 10/21/2025, 464 shares were sold at $187.95 to cover tax withholding and remittance obligations pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following these transactions, the officer directly owned 203,692 shares. Each RSU represents a right to receive one share. The RSUs vest over four years: 25% vested on January 20, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction on a Form 4. An officer serving as President, Clinical Diagnostics sold 292 shares of common stock at $187.95 on 10/21/2025. The filing states the sale was made to satisfy tax withholding obligations related to RSU vesting and was conducted under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Following the transaction, the officer beneficially owned 117,267 shares, held directly.
Natera, Inc. (NTRA) disclosed a Form 4 for its President and Chief Business Officer reporting a sale of 339 shares of common stock on 10/21/2025 at $187.95 per share (code S). The filing states the shares were sold to satisfy tax withholding and remittance obligations tied to vesting RSUs and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the transaction, the officer directly owned 152,408 shares.
Natera (NTRA) reported an insider transaction by its CEO and President, who is also a director. On 10/20/2025, 3,386 Restricted Stock Units vested and were converted to common stock (code M). On 10/21/2025, 1,603 shares were sold at $187.95 per share (code S) to satisfy tax withholding, under a Rule 10b5-1(c) instruction tied to a January 28, 2022 grant. Following these transactions, the reporting person directly beneficially owns 155,855 shares.
The RSU award vests over four years: 25% on January 20, 2023, with the remainder in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction by its chief financial officer. On Oct 20, 2025, 1,522 RSUs vested and were settled into common stock. On Oct 21, 2025, 602 shares were sold at $187.95 to satisfy tax withholding, pursuant to a written instruction intended to meet Rule 10b5-1(c) conditions. Following these transactions, the officer held 70,109 shares directly.
The RSUs relate to a grant dated Jan 28, 2022 and vest over four years: 25% vested on Jan 20, 2023, with the balance vesting in 12 equal quarterly installments thereafter.
Natera, Inc. filed a Form S-8 to register 3,600,000 additional shares of common stock under its Amended and Restated 2015 Equity Incentive Plan. The filing uses General Instruction E to add shares to a previously registered plan and incorporates prior S-8 filings by reference.
Natera is listed as a large accelerated filer. The registration includes standard indemnification disclosures for directors and officers and appends required exhibits, including a legal opinion and auditor consent.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
